Cost regulators for the National Health Service in England have asked for more information on the use of Novartis’ asthma blockbuster Xolair (omalizumab) for the treatment of hives, to determine whether or not it will endorse funding for the drug in this setting.

The National Institute for Health and Care Excellence said its Appraisal Committee is seeking clarification on a number of points to ensure an informed decision on cost-effectiveness can be made.

For more details, go to: http://www.pharmatimes.com/Article/14-11-19/NICE_asks_for_more_info_on_Xolair_for_hives.aspx?utm_source=dlvr.it&utm_medium=twitter